NYSEARCA:MJCO - NYSE Arca - US56068V1026
Private equity firm Thoma Bravo completes the acquisition of Majesco (NASDAQ:MJCO) at the revised go-private offer of $16/share in all-cash transaction.The acquisition price values the transaction at $729M.Majesco will cease trading from Sept.
Private-equity firm Clearlake Capital is buying Zywave from Aurora Capital Partners, the latest in a string of sales of an insurance technology company.
Majesco (NASDAQ:MJCO): Q1 GAAP EPS of $0.03.Revenue of $41.25M (+10.6% Y/Y)Press Release
NEW YORK, NY / ACCESSWIRE / August 22, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Majesco (NASDAQ:MJCO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo, L.P. for $13.10 per share. To learn more about your legal rights and options, visit:
Mentions: OTEL
NEW YORK, NY / ACCESSWIRE / August 15, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Majesco (NASDAQ:MJCO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo, L.P. for $13.10 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/majesco-mjco-stock-merger-thoma-bravo/. Otelco
Vertafore provides cloud-based software for the property and casualty insurance market.
Gainers Seres Therapeutics, Inc. (NASDAQ: MCRB) shares jumped 389.2% to close at $22.70 on Monday after the company announced the results from its SER-109 Phase 3 ECOSPOR III...
Gainers: CleanSpark (NASDAQ:CLSK) +34%. Majesco (NASDAQ:MJCO) +24%.
Gainers: Seres Therapeutics (NASDAQ:MCRB) +356%.Xtant Medical (NYSEMKT:XTNT) +70%.BiomX (NYSEMKT:PHGE) +51%.Omeros (NASDAQ:OMER) +47%.Adamas Pharmaceuticals (NASDAQ:ADMS) +31%.Trevena (NASDAQ:TRVN) +27%.Quest Resource (NASDAQ:QRHC) +21%.Usio (NASDAQ:USIO) +26%.CleanSpark (NASDAQ:CLSK) +25%.Majesco (NASDAQ:MJCO) +23%.Losers: Top Ships (NASDAQ:TOPS) -35%.Reata Pharmaceuticals (NASDAQ:RETA) -31%.Navidea Biopharmaceuticals (NYSEMKT:NAVB) -29%.Eastman Kodak (NYSE:KODK) -27%.Recro Pharma (NASDAQ:REPH) -25%.AzurRx BioPharma (NASDAQ:AZRX) -19%.Sohu.com (NASDAQ:SOHU) -18%.ZAGG (NASDAQ:ZAGG) -15%.Technical Communications (NASDAQ:TCCO) -14%.Momenta Pharmaceuticals (NASDAQ:MNTA) -14%.
Gainers Seres Therapeutics, Inc. (NASDAQ: MCRB) shares climbed 407% to $23.52 after the company announced the results from its SER-109 Phase 3 ECOSPOR III study in recurrent C....
Kodak shares tank after federal loan is put on halt. Foot Locker jumped on strong same-store sales data.
Majesco (NASDAQ:MJCO) signs an amended definitive agreement with PE firm Thoma Bravo for $16/share in the all-cash, go-private deal.The new price values the transaction at $729M.The price represents a roughly 113% premium over Majesco's average closing price during the 30-day period leading up to the original deal announcement on July 20.Thoma Bravo originally offered $13.10 in cash per Majesco share for a $594M transaction value.Majesco shares are up 22.5% pre-market to $16.03.
An unsolicited rival bid has spurred the private-equity firm to act.
Mentions: MYOS
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - MJCO, GSB, VAR, LVGO NEW YORK, NY / ACCESSWIRE / August 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Majesco (NASDAQ:MJCO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo, L.P. for
NEW YORK, NY / ACCESSWIRE / August 3, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Majesco (NASDAQ:MJCO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo, L.P. for $13.10 per share. To learn more about your legal rights and options, visit